NEW YORK (TheStreet) -- Agenus (AGEN) shares are up 16.7% to $3.75 on Tuesday after the company announced that its experimental cancer vaccine helped patients with brain tumors live twice as long as those that received treatment without the vaccine.
Fifty percent of newly diagnosed glioblastoma multiforme (GBM) patients treated with the vaccine had their median overall survival time increased to two years in a mid-stage study.
Most GBM patients succumb to the disease within one year.
Must Read: Warren Buffett's 25 Favorite Stocks
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.